Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | TACR3 | P29371 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712333 | 1.00 | KMT2A (0.62) | KMT2AMEN1ELANETACR3LMNA | |
| SCHEMBL8273800 | 1.00 | KMT2A (0.62) | KMT2AMEN1ELANETACR3LMNA | |
| Hydrochloric Acid SCHEMBL5223983 | 0.98 | KMT2A (0.60) | KMT2AMEN1ELANETACR3LMNA | |
| SCHEMBL12682597 | 0.84 | KMT2A (0.62) | KMT2AMEN1ELANETACR3LMNA | |
| SCHEMBL31679010 | 0.84 | KMT2A (0.62) | KMT2AMEN1ELANETACR3LMNA | |
| SCHEMBL13181743 | 0.84 | KMT2A (0.62) | KMT2AMEN1ELANETACR3LMNA | |
| SCHEMBL8284231 | 0.83 | SMN1; SMN2 (0.61) | KMT2AMEN1LMNATSHR | |
| SCHEMBL23593786 | 0.82 | KMT2A (0.60) | KMT2AMEN1ELANETACR3LMNA | |
| Hydrochloric Acid SCHEMBL31398429 | 0.82 | KMT2A (0.60) | KMT2AMEN1ELANETACR3LMNA | |
| SCHEMBL4574038 | 0.82 | KMT2A (0.60) | KMT2AMEN1ELANETACR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2017-10-26 | — | — | US | disclosed |
| US-9676771-B2 | Compounds for inhibiting drug-resistant strains of HIV-1 integrase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160083382-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | The United States of American, as represented by the Sec, Dept. of Health and Human Services (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2799422-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AND ALCOHOL BY HYDROLYSIS OF ESTER | National University Corporation Nagoya University (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-20140243333-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | UNIVERSITY OF KANSAS (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243333-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | UNIVERSITY OF KANSAS (US) | 2014-08-28 | — | — | US | disclosed |
| US-8735391-B2 | Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods | UNIVERSITY OF KANSAS (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735391-B2 | Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods | UNIVERSITY OF KANSAS (US) | 2014-05-27 | — | — | US | disclosed |
| US-20100256142-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | UNIVERSITY OF NORTH CAROLINA | 2010-10-07 | — | — | US | disclosed |
| US-7553969-B1 | Substituted phenethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7507820-B2 | Diazaphosphacycles | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1345918-B1 | 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256142-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | OPRM1, OPRK1, OPRL1 | KMT2A 903/4885MEN1 4180/4885ELANE 3936/4885 |
| US-20140243333-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | OPRM1, OPRK1, OPRD1 | KMT2A 1523/4885MEN1 3913/4885ELANE 3611/4885 |
| US-20170305904-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | KMT2A 1115/4885MEN1 4337/4885ELANE 2006/4885 |
| US-20160083382-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | CCR8, CDK8, CHD8 | KMT2A 1115/4885MEN1 4337/4885ELANE 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.